Vormatrogine
Epilepsy With Generalized Tonic-Clonic Seizures
Explore 5 assets in Epilepsy With Generalized Tonic-Clonic Seizures →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Praxis Precision Medicines
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07287163CT.gov Clinical Trial of Vormatrigine in Adult Patients With Epilepsy | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epilepsy With Generalized Tonic-Clonic Seizures
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vormatrogine (this asset) | Praxis Precision Medicines | P3 | B · 60 |
| Lamotrigine | GlaxoSmithKline | P4 | BBB |
| Midazolam | Pakistan Air Force (PAF) Hospital Islamabad | P4 | BB |
| Levetiracetam | Emory University | P4 | BB |
| Topiramate | GlaxoSmithKline | P3 | BB |
| Pregabalin | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | P3 | BB |
| Zonisamide | Affiliated Hospital of Nantong University | P4 | B |
| Phenytoin | Emory University | P4 | B |
| Fosphenytoin | Emory University | P4 | B |
+4 more in the Epilepsy With Generalized Tonic-Clonic Seizures cohort
Other indications for Vormatrogine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P3 | B · 60 |
| Generalized Epilepsy | — | P3 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vormatrogine in Epilepsy With Generalized Tonic-Clonic Seizures. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vormatrogine-epilepsy-with-generalized-tonic-clonic-seizures
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →